We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
- Authors
Mateos, Maria-Victoria; Richardson, Paul G; Schlag, Rudolf; Khuageva, Nuriet K; Dimopoulos, Meletios A; Shpilberg, Ofer; Kropff, Martin; Spicka, Ivan; Petrucci, Maria T; Palumbo, Antonio; Samoilova, Olga S; Dmoszynska, Anna; Abdulkadyrov, Kudrat M; Schots, Rik; Jiang, Bin; Esseltine, Dixie L; Liu, Kevin; Cakana, Andrew; van de Velde, Helgi; San Miguel, Jesús F
- Abstract
The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 13, p2259
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.26.0638